Biosimilar giant Biocon gets hit with 483 for issues at sites in Malaysia and India

Tyler Patchen

News Reporter

While Biocon continues to be one of the major players in the generics and biosimilars markets, several of the company’s manufacturing sites have ended up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biosimilar giant Biocon gets hit with 483 for issues at sites in Malaysia and India

Tyler Patchen

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

Is there room for MASH drugs in a GLP-1 world?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Biosim­i­lar gi­ant Bio­con gets hit with 483 for is­sues at sites in Malaysia and In­dia

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Biosimilar giant Biocon gets hit with 483 for issues at sites in Malaysia and India